Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 6 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Neurophysiological factors linked to GI symptoms in IBS

30 Jun 2020

Neurophysiological factors appear to play a role in gastrointestinal (GI) symptoms in patients with irritable bowel syndrome (IBS), a recent study has found.

The study included 281 IBS patients (median age, 36 years; 74 percent female), who showed normal median anxiety and depression levels. Among the neurophysiology factors were psychological distress, colonic and small intestinal motility, and small intestinal secretions, among others. Patients were not categorized according to different IBS subgroups for analyses.

Psychological distress, as a neurophysiology manifestation of the central nervous system, was significantly correlated with GI symptom severity, as were variables associated with rectal sensitivity (p<0.05). No such effect was found for small intestinal motility and secretion, rectal tone response, or autonomic nervous system function.

A total of 193 participants were able to complete the Gastrointestinal Symptom Rating Scale, IBS version (GSRS-IBS) and were eligible for subsequent multivariate analysis. In general, GI symptoms more strongly correlated with specific combinations of neurophysiological factors than with the total neurophysiological score.

“The benefit of this approach relative to assessing the neurophysiological factors individually was modest, further highlighting the complexity of symptom generation in IBS,” researchers said.

Notably, two neurophysiological factors were present in every reduced neurophysiology score: central nervous system function, manifested as psychological distress, and visceral sensitivity patterns. This suggested that these factors were the most crucial of GI symptoms in this cohort.

“Further studies with an expanded range of neurophysiological variables of importance for symptom generation in IBS can be considered,” researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 6 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.